Syndax Pharmaceuticals Inc. (SNDX) Upgraded to Hold at Zacks Investment Research
According to Zacks, “Syndax Pharmaceuticals, Inc. is a biopharmaceutical company which focused on the development and commercialization of entinostat, an epigenetic therapy for treatment-resistant cancers. The Company’s product pipeline includes ENCORE 601, ENCORE 602, J1353, NCI-7870, NCI-9844, E2112, NCI-8871 and NCI-9253 which are in clinical trial stage. Syndax Pharmaceuticals, Inc. is based in WALTHAM, United States. “
Several other equities analysts also recently commented on SNDX. JMP Securities reissued a buy rating on shares of Syndax Pharmaceuticals in a report on Wednesday, November 9th. Guggenheim assumed coverage on shares of Syndax Pharmaceuticals in a report on Friday, October 7th. They issued a buy rating and a $29.00 target price on the stock. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus target price of $25.80.
Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) opened at 9.88 on Thursday. The stock has a 50 day moving average of $12.41 and a 200 day moving average of $12.90. The stock’s market capitalization is $179.75 million. Syndax Pharmaceuticals has a 52-week low of $8.97 and a 52-week high of $18.03.
A number of large investors have recently added to or reduced their stakes in the stock. Jennison Associates LLC increased its stake in Syndax Pharmaceuticals by 16.6% in the second quarter. Jennison Associates LLC now owns 537,545 shares of the company’s stock worth $5,247,000 after buying an additional 76,653 shares during the last quarter. Kornitzer Capital Management Inc. KS increased its stake in Syndax Pharmaceuticals by 13.8% in the second quarter. Kornitzer Capital Management Inc. KS now owns 45,500 shares of the company’s stock worth $448,000 after buying an additional 5,500 shares during the last quarter. Alps Advisors Inc. acquired a new stake in Syndax Pharmaceuticals during the second quarter worth about $246,000. Schwab Charles Investment Management Inc. acquired a new stake in Syndax Pharmaceuticals during the second quarter worth about $100,000. Finally, BlackRock Advisors LLC increased its stake in Syndax Pharmaceuticals by 232.7% in the second quarter. BlackRock Advisors LLC now owns 1,026,902 shares of the company’s stock worth $10,115,000 after buying an additional 718,209 shares during the last quarter. 57.82% of the stock is currently owned by institutional investors.
About Syndax Pharmaceuticals
Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.
Receive News & Stock Ratings for Syndax Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.